Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 Operating Margin % is 22.40% as of Mar. 2026, which is 14% above its 10-year median of 19.58. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 959 Drug Manufacturers companies, Techno Drugs ranks better than 85.19% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Techno Drugs's Operating Income for the
three
months ended in Mar. 2026 was BDT137 Mil. Techno Drugs's Revenue for the
three
months ended in Mar. 2026 was BDT612 Mil. Therefore, Techno Drugs's Operating Margin % for the quarter that ended in Mar. 2026 was 22.40%.
The historical rank and industry rank for Techno Drugs's Operating Margin % or its related term are showing as below:
DHA:TECHNODRUG'
s Operating Margin % Range Over the Past 10 Years
Min: 18.46 Med: 19.58 Max: 22.28
Current: 22.28
DHA:TECHNODRUG's Operating Margin % is ranked better than 85.19% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs DHA:TECHNODRUG: 22.28
Techno Drugs's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Techno Drugs's Operating Income for the
three
months ended in Mar. 2026 was BDT137 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT691 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Techno Drugs Operating Margin % Related Terms
Techno Drugs Operating Margin % Historical Data
* Premium members only.
The historical data trend for Techno Drugs's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Techno Drugs's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Techno Drugs's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a Operating Margin % of 22.40% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Techno Drugs and its competitors. This is 14% above median its historical median of 19.58. Over the past decade, Techno Drugs' Operating Margin % has ranged from 18.46 to 22.28. According to the industry distribution chart, Techno Drugs ranks #142 out of 959 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Techno Drugs' Operating Margin % too high?
Techno Drugs' current Operating Margin % of 22.40% is 14% above median its 10-year median of 19.58. Over the past 10 years, this metric has ranged from a low of 18.46 to a high of 22.28. The Drug Manufacturers industry median Operating Margin % is 7.57. Techno Drugs' value of 22.40% is 195.9% above this industry median. Based on the distribution chart, Techno Drugs ranks #142 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #142 out of 959 companies for Operating Margin %. This places Techno Drugs in the top 15% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.57. Techno Drugs' value of 22.40% is 195.9% above this benchmark. Historically, Techno Drugs' own Operating Margin % has ranged from 18.46 to 22.28 over the past decade. While the company's 10-year median is 19.58 vs. the industry median of 7.57, Techno Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current Operating Margin % of 22.40% is 195.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current Operating Margin % is 22.40%, which is 14% above median its own 10-year median of 19.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Operating Margin % of 22.40%. The current Operating Margin % is 22.40%, which is 14% above median its 10-year median of 19.58 and 195.9% above the Drug Manufacturers industry median of 7.57. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Operating Margin % is 22.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
